secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001558370-25-006866
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood Therapeutics Q1 2025 net loss $12.2M; Halneuron Phase 2b dosing underway
--------------------------------------------------------------------------------

- Net loss of $12.2M ($8.45 per share) vs $1.3M ($1.68) in Q1 2024; R&D spend rose to $2.4M.
- Halneuron Phase 2b CINP study initiated; interim data readout expected Q4 2025.
- $19.5M loan from CK Life Sciences affiliate converted to equity; $4.8M gross common stock raise.
- Cash and equivalents of $17.5M provides operational runway through Q1 2026.
- Regained Nasdaq compliance with minimum stockholders' equity of $2.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837025006866/0001558370-25-006866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837025006866/dwtx-20250508x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-006866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer